AptaBio Therapeutics Inc (KQ:293780) — Market Cap & Net Worth
Market Cap & Net Worth: AptaBio Therapeutics Inc (293780)
AptaBio Therapeutics Inc (KQ:293780) has a market capitalization of $89.35 Million (₩131.85 Billion) as of June 17, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #19737 globally and #1022 in its home market, demonstrating a -8.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AptaBio Therapeutics Inc's stock price ₩4905.00 by its total outstanding shares 26881360 (26.88 Million). Review AptaBio Therapeutics Inc total liabilities to assess the company's total debt and financial obligations.
AptaBio Therapeutics Inc Market Cap History: 2019 to 2026
AptaBio Therapeutics Inc's market capitalization history from 2019 to 2026. Data shows change from $315.16 Million to $89.35 Million (-17.83% CAGR).
Index Memberships
AptaBio Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$279.47 Billion | 0.03% | #435 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$279.47 Billion | 0.03% | #435 of 1384 |
Weight: AptaBio Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AptaBio Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AptaBio Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
AptaBio Therapeutics Inc's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $315.16 Million | $1.02 Billion | -$6.30 Billion | 0.31x | N/A |
| 2020 | $462.71 Million | $341.04 Million | -$3.92 Billion | 1.36x | N/A |
| 2021 | $677.68 Million | $223.68 Million | -$10.69 Billion | 3.03x | N/A |
| 2022 | $194.01 Million | $48.35 Million | -$10.56 Billion | 4.01x | N/A |
| 2023 | $164.86 Million | $323.87 Million | -$12.06 Billion | 0.51x | N/A |
| 2024 | $116.04 Million | $3.36 Billion | -$29.38 Billion | 0.03x | N/A |
Competitor Companies of 293780 by Market Capitalization
Companies near AptaBio Therapeutics Inc in the global market cap rankings as of June 17, 2026.
Key companies related to AptaBio Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
AptaBio Therapeutics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, AptaBio Therapeutics Inc's market cap moved from $315.16 Million to $ 89.35 Million, with a yearly change of -17.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩89.35 Million | -47.54% |
| 2025 | ₩170.33 Million | +46.78% |
| 2024 | ₩116.04 Million | -29.61% |
| 2023 | ₩164.86 Million | -15.02% |
| 2022 | ₩194.01 Million | -71.37% |
| 2021 | ₩677.68 Million | +46.46% |
| 2020 | ₩462.71 Million | +46.82% |
| 2019 | ₩315.16 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of AptaBio Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $89.35 Million USD |
| MoneyControl | $89.35 Million USD |
| MarketWatch | $89.35 Million USD |
| marketcap.company | $89.35 Million USD |
| Reuters | $89.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AptaBio Therapeutics Inc
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing n… Read more